Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Takara Bio Forward PE Ratio Related Terms
Takara Bio Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Takara Bio's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takara Bio Forward PE Ratio Chart
Takara Bio Annual Data
Trend
2018-03
2019-03
2025-03
Forward PE Ratio
89.29
78.74
22.08
Takara Bio Quarterly Data
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2024-12
2025-03
2025-06
2025-09
2025-12
Forward PE Ratio
89.29
82.64
113.64
75.76
78.74
60.98
29.66
22.08
28.21
49.51
34.21
FRA:TF2 vs VRTX, REGN, ALNY: Forward PE Ratio Comparison
For the Biotechnology subindustry, Takara Bio's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Takara Bio's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Takara Bio (FRA:TF2) has a Forward PE Ratio of 35.09 as of Jul. 22, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Takara Bio and its competitors. According to the industry distribution chart, Takara Bio ranks #236 out of 355 companies in the Biotechnology industry, placing it in the top 66.5%.
Is Takara Bio's Forward PE Ratio too high?
Takara Bio's current Forward PE Ratio is 35.09. The Biotechnology industry median Forward PE Ratio is 22.19. Takara Bio's value of 35.09 is 58.1% above this industry median. Based on the distribution chart, Takara Bio ranks #236 out of 355 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Takara Bio has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #236 out of 355 companies for Forward PE Ratio. This places Takara Bio in the lower half of its industry. The industry median Forward PE Ratio is 22.19. Takara Bio's value of 35.09 is 58.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.19, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takara Bio's current Forward PE Ratio of 35.09 is 58.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current Forward PE Ratio is 35.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Takara Bio (FRA:TF2) has a current Forward PE Ratio of 35.09. The stock's GF Value™ is €4.48, compared to a current price of €5.95 — trading 32.8% above its estimated fair value. The current Forward PE Ratio is 35.09 and 58.1% above the Biotechnology industry median of 22.19. Takara Bio's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Forward PE Ratio is 35.09 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 32.8% above its estimated GF Value™ of €4.48.
Key valuation signals for FRA:TF2:
Forward PE Ratio: 35.09
GF Value™: €4.48 vs. price of €5.95 (32.8% above fair value)
Industry Position: 58.1% above the Biotechnology median (#236 of 355)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
50GF Score
Get the complete analysis for FRA:TF2
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
